TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
122 hedge funds and large institutions have $136M invested in TCR2 Therapeutics Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 34 increasing their positions, 35 reducing their positions, and 32 closing their positions.
25% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 32
4% more funds holding
Funds holding: 117 → 122 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 35
50% less capital invested
Capital invested by funds: $270M → $136M (-$134M)
57% less call options, than puts
Call options by funds: $123K | Put options by funds: $288K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.23M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$7.08M |
| 3 |
Renaissance Technologies
New York
|
+$4.36M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$3.6M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$15.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.25M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$5.28M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.91M |
TCRR Hedge Fund Activity: Q4 2021 in Review
122 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q4 2021, worth a combined $136M — down 50% from $270M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new TCRR positions and 32 closed out — a net gain of 8 holders — while 34 added to existing stakes and 35 trimmed.
The largest buyer was Millennium Management, adding an estimated $7.23M. The largest seller was Redmile Group, cutting an estimated $15.4M.
- 122 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q4 2021, up from 117 in Q3 2021.
- Funds reported $136M of TCR2 Therapeutics Inc. Common Stock stock for Q4 2021, down 50% quarter-over-quarter.
- 40 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q4 2021 and 32 closed out, a net change of +8 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q4 2021 was Millennium Management, an estimated $7.23M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q4 2021 was Redmile Group, an estimated $15.4M sold.
Based on aggregated 13F filings for Q4 2021.